Kura Oncology (KURA) stock
NASDAQ
As of the Nov 17, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $688M
- As of Nov 17, 2026
- P/E
- -2.35x
- Trailing twelve months
- P/B
- 38.22x
- Latest reported equity
- P/S
- 8.71x
- Trailing twelve months
- ROE
- -1,627.8%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 17, 2026 and may differ from the current price.
- Market cap
- $688M
- As of Nov 17, 2026
- P/E
- -2.35x
- Trailing twelve months
- P/B
- 38.22x
- Latest reported equity
- P/S
- 8.71x
- Trailing twelve months
- ROE
- -1,627.8%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 17, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-2.35x
Net loss — not comparable
P/B
38.22x
P/S
8.71x
Earnings and dividend metrics▾
Earnings
EPS
-$3.18
Earnings per share
BPS
$0.20
Book value per share
ROE
-1,627.8%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $3.18 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $0.20 of net assets.
- ROE — shareholder equity shrank by 1,627.8% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 9.5% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $21M+9.5%
—
Jul–Sep '24
$21M
Jul–Sep '25
$23M
Jul–Sep '26
Blank bars mark quarters with no figure found in the filings.
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 10, 2026.
- Earnings per share increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Revenue increased 9.5% from the same quarter a year earlier.
- Operating income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
Filed Nov 10, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- WILSON TROY EDWARDPresident and CEO · Nov 16, 2026Open-market purchase202,238 shares · $1.5MAvg. price $7.42
Show 2 price lots
- 101,119 shares × $7.42$750K
- 101,119 shares × $7.42$750K
- WILSON TROY EDWARDPresident and CEO · Nov 13, 2026Open-market purchase197,762 shares · $1.5MAvg. price $7.63
Show 2 price lots
- 98,881 shares × $7.63$754K
- 98,881 shares × $7.63$754K
- Leoni MollieChief Medical Officer · Sep 29, 2026Open-market sale28,802 shares · $310KAvg. price $10.7481141,095 shares held after
- Powl Brian T.Chief Commercial Officer · Sep 29, 2026Open-market sale15,430 shares · $166KAvg. price $10.7487136,819 shares held after
- FORD KATHLEENChief Operating Officer · Sep 29, 2026Open-market sale3,668 shares · $39KAvg. price $10.7516142,986 shares held after
- Leoni MollieChief Medical Officer · Sep 28, 2026Open-market sale12,448 shares · $131KAvg. price $10.4973169,897 shares held after
- Powl Brian T.Chief Commercial Officer · Sep 28, 2026Open-market sale17,020 shares · $179KAvg. price $10.5278
Show 2 price lots
- 9,020 shares × $10.4973$95K
- 8,000 shares × $10.5622$84K
- Bair Teresa BrophyChief Legal Officer · Sep 28, 2026Open-market sale8,442 shares · $89KAvg. price $10.4973187,002 shares held after
- FORD KATHLEENChief Operating Officer · Sep 28, 2026Open-market sale6,906 shares · $72KAvg. price $10.4973146,654 shares held after
- DOYLE THOMAS JAMESSVP, Finance & Accounting · Sep 28, 2026Open-market sale4,607 shares · $48KAvg. price $10.4972142,428 shares held after
- Burrows FrancisChief Scientific Officer · Sep 24, 2026Open-market sale20,726 shares · $225KAvg. price $10.832542,327 shares held after
- Burrows FrancisChief Scientific Officer · Sep 24, 2026Option exercise30,000 shares · $185KAvg. price $6.1563,053 shares held after
- WILSON TROY EDWARDPresident and CEO · Aug 24, 2026Open-market purchase100,000 shares · $1.2MAvg. price $12.39479,194 shares held after
- Powl Brian T.Chief Commercial Officer · Aug 21, 2026Open-market sale4,345 shares · $52KAvg. price $11.8903169,269 shares held after
- Bair Teresa BrophyChief Legal Officer · Aug 19, 2026Open-market sale31,487 shares · $398KAvg. price $12.63195,444 shares held after
- WILSON TROY EDWARDPresident and CEO · Aug 17, 2026Open-market purchase100,000 shares · $1.1MAvg. price $11.12379,194 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Kura Oncology (KURA) stock information
NASDAQ
Kura Oncology (KURA) is listed on NASDAQ. Its market capitalization is about $688M. On trailing-twelve-month earnings the P/E ratio is -2.35, and the P/B ratio is 38.22. Return on equity is -1627.8%. These figures are computed in-house from official filings and are reference information only.
Kura Oncology — frequently asked questions
- What is the P/E ratio of Kura Oncology (KURA)?
- On a trailing-twelve-month basis, KURA trades at a P/E ratio of -2.35. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Kura Oncology?
- KURA has a market capitalization of about $688M. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.